Regeneron Pharmaceuticals (REGN +2.8%) is added to Bank of America's "U.S. 1 List," calling the...

Regeneron Pharmaceuticals (REGN +2.8%) is added to Bank of America's "U.S. 1 List," calling the company one of its top biotech picks for 2012. The firm says it sees upside to its above-consensus 2012 Eylea sales forecast of $350M, stemming from positive physician sentiment toward dosing frequency advantages for the eye treatment.